# Study of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCL

> **NCT04913103** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Czech Lymphoma Study Group** · enrollment: 21 (estimated)

## Conditions studied

- Lymphoma, Mantle-Cell

## Interventions

- **DRUG:** Polatuzumab vedotin
- **DRUG:** Bendamustine Hydrochloride
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT04913103
- **Lead sponsor:** Czech Lymphoma Study Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2021-09-01
- **Primary completion:** 2026-08-31
- **Final completion:** 2027-08-31
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2021-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04913103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04913103, "Study of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCL". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04913103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*